The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India’s subsidiary -- Granules Pharmaceuticals, through its US agent First Time US Generics LLC, for Methylphenidate Hydrochloride Extended-Release Tablets USP, 10 mg and 20 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug ‘Ritalin SR Sustained-Release Tablets, 20 mg’ of Novartis Pharmaceuticals Corporation. Granules Pharmaceuticals shall market and distribute the product shortly.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.45 |
| Dr. Reddys Lab | 1235.10 |
| Cipla | 1233.00 |
| Zydus Lifesciences | 939.95 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: